Researchers at Keele University have published the first investigation into the variation in the chemical makeup of ...

Investigators compared early oncologic outcomes by staging modality among men diagnosed with very high-risk prostate cancer.

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most ...

Research confirms that many men with nonmetastatic prostate cancer will not die of their disease once they received recommended treatment.

EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...

The rising median age of people around the world has the same effect, since cancer can take decades to develop and therefore ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes.

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

New research in the July 2025 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that for people diagnosed with nonmetastatic low-risk prostate cancer later in life, and treated ...

Cancer is a disease whose very name evokes despair in the mind and heart. The patient often loses inner strength, feeling as ...

The purpose of these estimates is to inform state and local cancer care organizations and providers, patient support programs and educators, advocates, and researchers so they can allocate resources ...